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When prostaglandins (PCs) were introduced in clinical medicine in
the late 1960s, there were good hopes that these novel drugs would
revolutionize the entire field of reproduction and fertility regu-
lation. While it is clear that this has not been the case, their
impact has nonetheless been substantial. In.pregnancy, their ef-
fects encompass three different mechanisms: luteolysis, uterine
stimulation and cervical compliance, but only the last two can be
successfully influenced in man.Although all clinical use of PCs thus
aims to pharmacologically influence either one or both of these
mechanisms, the goals that need to be achieved and the available
means have hitherto resulted in six different types of application:
1) induction of labour; 2) pre-labour cervical ripening; 3) pre-
operative cervical dilatation; 4) induced abortion; 5) management
of antepartum fetal death; and 6) postpartum uterine atony. De-
spite the fact that this subdivision of clinical uses contains
several elements of artificiality, there are sound clinical rea-
sons for considering each of these as a distinct entity.' While the
applications which are considered in this presentation are not the
most frequent ones, in our opinion they contain the two most im-
portant contributions of PCs to clinical obstetrics: management of
fetal death and of uterine atony.
Induction of abortion and pre-operative cervical dilatation
In the first trimester, none of the known PG regimeris can match
the convenience and acceptability of vacuum aspiration under local
anaesthesia. Moreover, PCs do not preclude the need for vacuum as-
piration, since the incidence of incomplete abortion (20 to 50+ %
depending on method and gestational age) is high enough to warrant
mechanical evacuation in all cases. Despite the vaste literature
on pre-operative dilatation with various PCs in early pregnancy, it
is dubious whether cost-benefit analyses could sustain claims that
such procedures should henceforth be adopted for routine use.
Nevertheless, selective use of PCs to lower cervical resistance in
women with an unyielding and rigid cervix is likely to be superior
to forceful dilatation, although the choice of PG and the dose and
route of administration cannot be fixed at present. High success
rates in a reasonably short interval of 3-4 hours can be achieved
with vaginal 0.5-1 mg suppositories of 16,16-dimethyl-PGE anal-
ogues, with 500 yg (or possibly 250 yg) sulprostone intramuscular-
ly or 25 yg sulprostone intra-cervically (injected 3-4 cm deep in
the cervical tissues).
PCs have established a major role in terminating second trimester
pregnancy, but successful application depends on a large number of
variables (Table I ) . Systemic administration of natural PCs 'is now
obsolete. Intra-amniotic administration of PGE2 and PGF2a is only
suitable beyond 15 weeks and requires either high doses or repeat
injections to achieve reasonable success. Gastrointestinal side
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side effects/ risk of cervical injuries and the need for enhance-
ment with oxytocin are serious limitations. Extra-amniotic instil-
lation of 200 yg PGE2 or 750 yg PGF2ot two-hourly or equivalent
amounts by continuous
infusion result in a TABLE 1 — Variables known to influence the effectiveness, com-
plication rate and incidence of side effects of termination ofpreg-
nancy with prostaglandins.high success rate with
a low incidence of side
effects, but oxytocin
may be needed in up to
50 % of patients and
the method is rather
cumbersome. The use of
a viscous gel (e.g.
with 2-3 mg PGE2) lim-
its the need for fre-
quent or continuous dos-
age, but mostly a re-
peat dose or oxytocin
remain required. Natural
PCs have therefore been
]
· Nature of the prostaglandin
(E2, F2ft, analogue)
2. Dose used
3. Preparation used
(solution, pessary, gel, ...)
4. Route of administration
— systemic (vaginal, intravenous, intramuscular, . . .)
- local (intraamniotic, extraamniotic)
5. Frequency of administration
(single dose, repeat, continuous, ...)
6. Augmentation with other methods
(laminaria tents, oxytocin infusion, intraamniotic urea or
saline, ...)
7. Type of pregnancy
largely replaced £>y anal (viable pregnancy, molar pregnancy, intrauterine fetal
death)ogues, although much de-
pends on the availability. 8. Gestational age
The main reasons have
been: resistance to
degradation by 15-hydroxy-prostaglandin dehydrogenase (which re-
sults in longer half-life and better systemic administration) and
higher uterospecificity. Many analogues have been tested, but of
those currently available in Europe, sulprostone (multi-substitu-
ted PGE2 analogue) appears to be the best choice. So far, it is
not clear whether the recommended doses of 0.5 mg i.m. every 4 hrs,
1.5 mg i.v. during 6 hrs or 1.0 mg i.v. during 10 hrs provide ideal
dose schedules. The cumulative experience may well contain a plea
for examining lower and less arbitrary dose schedules.
Management of antepartum fetal death
Fetal death now occurs on average earlier in pregnancy and is di-
agnosed more readily, thereby increasing the need for effective
termination. PCs will terminate such pregnancies more readily
(shorter interval; lower dose) than viable pregnancies of similar
duration. Nevertheless the disadvantages of natural PGs still
aPply· Oral and vaginal routes require an advanced gestational age,
some spontaneous contractility or a ripe cervix to overcome inef-
fectiveness and side effects. Intra-amniotic instillation is unsafe.
Extra-amniotic administration combines high efficacy with few side
effects but can be cumbersome. Several analogues have shown a high
effectiveness but there has been little attention to optimal dos-
age and most studies have undoubtedly used excessive doses and/or
irrational schedules of administration. Presently, there is a near
100 % chance of induction-delivery intervals< 24 hours with i.m.
injections of 15-methyl-PGF2a (250 yg/2 hrs) or sulprostone
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(500 yg/4-6 hrs) , though side effects are less prominent with the
latter. In multiparous women 125 yg 15-me-PGF2a is at least as
effective as 250 yg. With pharmacological data, thiW indicates
that recommended doses of both, and sulprostone in particular may
be well in excess of what is required. Similarly, for adequate
efficacy i.v. infusion rates of sulprostone should probably never
exceed 2 yg/min.
Postpartum haemorrhage due to uterine atony
Since Tagaki et al. pioneered the use of PCs to control moderate
to severe postpartum bleeding, there have been numerous reports on
the successes that have been achieved with various PCs administered
by various routes. The former have included PGE2, PGF2ot/ 15-me-
PGF2a/sulprostone and the latter include i.m., i .V., vaginal/
intra-cavitary, intra-cervical and -intra-myometrial via abdominal
or vaginal routes. All reports have dealt with a few cases at
most; negative results are unlikely to be reported.or published;
and there are hitherto no randomized controlled trials (one trial
using the prophylactic approach showed 250 yg 15-me-PGF2a i.m. to
be more effective than 125 or 62.5 yg but with significant gastro-
intestinal side effects). Despite this lack of controlled data, in
many instances, including our own experience, PGs were resorted to
as ultimate step prior to radical surgery. Not surprisingly in
these circumstances an incredible dose range has been used. While
emphasizing the uncontrolled nature of the data and the need for
an adequately controlled trial, on the basis of the available data
it may be tentatively concluded that intramyometrial injection
(either at caesarean section, transabdominally or vaginally in
the lower segment) of 250 yg sulprostone, 125 yg 15-me-PGF2a or
1000 yg PGF2a may control severe postpartum haemorrhage caused by
uterine atony. At the same time, comparison of these.dosages of
different PGs should indicate the ad hoc nature of that conclusion.
Conclusion:
Unfortunately, comparison of various PGs for the indications dis-
cussed above still shows major limitations. On the one hand,
this is due to heterogeneity of parameters such as gastrointesti-
nal side effects, percentage of success, time interval required to
achieve such success, potential or real hazards, etc. all of which
may be valued differently and are difficult to weigh" against each
other. On the other hand, the main causes still relate to the
availability of PGs with different compounds being available in
different countries. Rational choice of future therapies will ob-
viously require a solution to such problems.
